Drug intelligence / Profile preview

bavtavirine

Development stage: Phase 1
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral

Overview

Bavtavirine is an investigational antiretroviral drug candidate. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed for the treatment of HIV-1 infection. Bavtavirine acts by binding to and inhibiting the activity of HIV-1 reverse transcriptase, thereby blocking viral replication. The drug has been studied in clinical trials as a potential therapy for patients with HIV, particularly those with resistance to other NNRTIs. As of now, it remains in development and has not received regulatory approval.

Targets

Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on bavtavirine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bavtavirine.

Explore the full profile